Skip to main content

Polylactic Acid Filler — Penile Girth Augmentation

Polylactic acid (PLA) filler is a biostimulatory injectable used for penile girth enhancement. Rather than providing immediate volumetric augmentation like hyaluronic acid (HA), PLA induces endogenous neocollagenesis — a more gradual but potentially more durable augmentation effect.[1][2] It is the second most studied injectable filler for penile augmentation after HA, with the most rigorous comparative data from a series of multicenter RCTs.[3][4][5] For positioning vs other male cosmetic options see Cosmetic Genital Surgery — Male.

Society positioning

The SMSNA 2024 Position Statement characterizes most non-surgical and surgical penile-augmentation procedures as investigational. PLA is FDA-approved for facial lipoatrophy / wrinkles only — penile use is entirely off-label. Psychosexual counseling should precede any intervention.

Mechanism — biostimulatory vs volumetric​

PLA is a synthetic, biocompatible, biodegradable polymer that functions as a biostimulatory scaffold rather than a conventional space-filling filler.[2][6]

The regenerative cascade[7][6][8][2]:

  1. Subclinical foreign body response — PLA microparticles elicit a controlled inflammatory tissue response with M2 macrophage polarization.
  2. Fibroblast activation — macrophage-mediated upregulation of TGF-β1 / TGF-β2, IL-1β, and CXCL6 activates resident fibroblasts.
  3. Neocollagenesis — stimulated fibroblasts produce type I and type III collagen, creating new volume through autologous tissue rather than exogenous material.
  4. Gradual degradation — PLA microparticles metabolized to CO₂ and H₂O via the Krebs cycle and expelled through the respiratory system; the newly formed collagen persists.

This mechanism explains the distinct temporal profile: gradual onset of augmentation but potentially longer-lasting results, since the volume is composed of the patient's own collagen rather than an exogenous gel that undergoes enzymatic degradation.[2]

FDA approval and regulatory status​

PLA (marketed as Sculptra / Sculptra Aesthetic in the US) was FDA-approved in 2004 for HIV-associated facial lipoatrophy and in 2009 for cosmetic correction of nasolabial-fold contour deficiencies and other facial wrinkles in immunocompetent patients.[9][10][11] Penile use is entirely off-label. In facial applications, therapeutic effects last approximately 2 years.[10][12]

Clinical evidence​

The penile-PLA evidence base derives almost entirely from a single research group (Yang et al.) — a foundational prospective study followed by three multicenter, patient/evaluator-blinded RCTs.

Yang 2017 — foundational PLA monotherapy​

23 healthy men, mean injected volume 20 mL.[1]

  • Proximal / mid- / distal-shaft circumference increased by mean +2.2, +2.7, +2.7 cm at 3 months (each p < 0.001).
  • Stable augmentation at 18 months — no significant change between time points (p > 0.05).
  • VAS satisfaction 51.6 → 74.3 at 6 months (p < 0.001).

Head-to-head RCTs vs HA​

TrialnFollow-upPLA girth gainHA girth gainBetween-groupSatisfactionAE rate (PLA vs HA)
Yang 2019 J Sex Med 48-wk RCT[3]7248 wk+13.49 mm (p < 0.001)+16.95 mm (p < 0.001)HA > PLA at 4 wk (p < 0.001); NS at 48 wk (p = 0.075)comparable (p > 0.05)8.3% vs 2.8%
Yang 2020 J Sex Med 24-wk RCT[4]7424 wk+1.6 cm (p < 0.001)+2.1 cm (p < 0.001)HA > PLA (0.5 cm, p = 0.031)comparable (p = 0.950)14.3% vs 5.1% (p = 0.245)
Yang 2020 J Clin Med 18-mo RCT[5]6718 mosignificant (p < 0.001)significant (p < 0.001)NS during entire study periodcomparable (p > 0.05)5.9% vs 9.1%

Key comparative findings​

  • Early augmentation: HA > PLA at 4 weeks (p < 0.001) — HA's volumetric effect is immediate while PLA's collagen-stimulating mechanism is gradual.[3]
  • Convergence over time: difference narrows progressively and becomes non-significant by 48 weeks as HA resorbs while PLA-stimulated collagen accumulates.[3]
  • At 18 months: both fillers maintain significant augmentation; difference NS during the entire study period.[5]
  • Satisfaction: no significant differences in appearance, sexual life, or BPSS psychological-distress improvement.[4][5]
  • Psychological benefits: both fillers significantly reduced BPSS scores (5.3–7.8 points, p < 0.05).[4]

Durability — PLA's principal clinical advantage​

The most clinically significant distinction between PLA and HA for penile augmentation is durability:

  • PLA: girth gains stable from 3 to 18 months with no significant attenuation (p > 0.05 between time points).[1][5]
  • HA: girth gains peak at 1 month and progressively attenuate, retaining ~ 70–75% of peak augmentation at 12 months.[13]

Consistent with PLA's biostimulatory mechanism — once neocollagenesis has occurred, the newly formed collagen persists even as PLA microparticles degrade. Facial-application data report PLLA effects lasting up to 2 years or longer.[12][14] Whether this same durability extends beyond 18 months in penile tissue is unknown — no longer-term penile-augmentation data exist.

Safety​

PLA penile augmentation has a favorable safety profile comparable to HA.[4][5][3][1]

  • Overall AE rate 5.9–14.3% across RCTs; all mild and transient.
  • No serious adverse events in any penile-augmentation study.
  • No statistically significant difference in AE rates vs HA (p = 0.245).[4]

Reported AEs in penile PLA injection​

  • Injection-site discomfort / pain.
  • Transient edema.
  • Subcutaneous nodules (palpable, non-visible).
  • Bruising.

Considerations from facial-PLA literature (potentially applicable)​

  • Papules and nodules — most commonly discussed PLA-specific complication. In facial applications, arise several weeks after injection, generally palpable but non-visible, typically resolve spontaneously. Result from suboptimal product reconstitution or placement; minimized by improved technique.[15]
  • True inflammatory granulomas — very rare in facial use (incidence 0.01–0.1%), systemic in nature, may appear months to years post-injection and may persist / grow. Treatment: intralesional steroids and antimetabolites (5-fluorouracil).[15][16]
  • Late-onset immune-mediated reactions — Alijotas-Reig 2009 case series of 10 non-HIV patients: mean latency 19.2 months (range 6–60) to onset of delayed adverse effects (tender inflammatory nodules, facial edema). At 50-mo follow-up: 50% in remission, 40% with recurrent episodes.[16]
  • Wortsman 2025 international ultrasound study — PLA accounted for 18.8% of all filler-related granulomas (second only to HA at 50.4%); likely reflects usage volume rather than inherent risk.[17]
Non-reversibility — critical distinction from HA

Unlike HA (which can be dissolved with hyaluronidase), PLA cannot be enzymatically reversed.[15] If nodules, asymmetry, or overcorrection occur, management options are limited to observation, intralesional corticosteroids, 5-fluorouracil, or surgical excision.[15][18] Non-reversibility makes precise injection technique and patient selection more critical for PLA than for HA. Final result is not fully apparent until weeks to months after injection — making overcorrection more difficult to predict.[2]

Injection technique​

The specific PLA injection technique for penile augmentation is less well-described than for HA. General principles from the RCTs and facial-application literature[4][3][1]:

  • Volume: mean ~ 20 mL.[1]
  • Plane: subcutaneous / dartos fascia layer, similar to HA.
  • Reconstitution: PLA is supplied as a lyophilized powder requiring reconstitution. Adequate reconstitution time and dilution volume are critical to minimize nodule formation. Lessons learned from facial use recommend higher-volume dilution and adequate hydration time.[19][20]
  • Post-injection massage: "5-5-5 rule" from facial use — massage 5 times daily for 5 minutes for 5 days.[9]
  • Treatment sessions: facial PLA is often administered over 2–4 sessions spaced 4–6 weeks apart to allow gradual collagen buildup and avoid overcorrection. The penile-augmentation studies used a single injection session.[9][19][1]

PLA vs HA — comparative summary​

FeaturePLAHA
MechanismBiostimulatory (neocollagenesis)Volumetric (space-filling)
OnsetGradual (weeks to months)Immediate
Peak girth gain+1.3–2.7 cm+1.7–3.9 cm
Early augmentation (4 wk)Less than HA (p < 0.001)Greater than PLA
Long-term (48 wk–18 mo)Comparable to HA (p > 0.05)Comparable to PLA
DurabilityStable 3–18 mo (no significant attenuation)Progressive attenuation (~ 70–75% at 12 mo)
ReversibilityNot reversibleReversible with hyaluronidase
AE rate5.9–14.3% (mild)5.1–9.1% (mild)
Nodule / granuloma riskTheoretically higher (from facial data)Lower
SatisfactionComparable to HAComparable to PLA
FDA-approved indicationFacial lipoatrophy / wrinkles (penile use off-label)Facial soft tissue augmentation (penile use off-label)

Limitations of current evidence​

  • Single research group — nearly all penile-PLA data come from Yang et al., limiting generalizability.[3][4][5][1]
  • High dropout rates — up to 43.1% in the 48-week RCT.[3]
  • No data beyond 18 months for penile augmentation — the theoretical advantage of longer durability remains unproven in this specific application.[5]
  • No standardized penile injection protocol — reconstitution volumes, dilution ratios, and injection techniques are not standardized for penile use.[21]
  • Nodule / granuloma risk in penile tissue is unknown — penile tissue has unique biomechanical properties (repeated stretching, compression, friction) that may affect PLA microparticle behavior differently than facial tissue.
  • Non-reversibility limits the safety margin compared to HA, particularly in an off-label application without established guidelines.
  • Overall low quality of evidence — Manfredi 2022 narrative review noted 89.7% of penile-girth-enhancement studies are not RCTs.[22]

Where PLA fits — clinical decision-making​

PLA may be preferred when patients:

  • Prioritize longer-lasting results and wish to minimize retreatment frequency.
  • Accept the gradual onset of augmentation (weeks to months rather than immediate).
  • Understand and accept non-reversibility.

HA may be preferred when patients:

  • Desire immediate visible results.
  • Value the safety net of reversibility with hyaluronidase.
  • Are undergoing penile augmentation for the first time and wish to "trial" the effect before committing to a non-reversible option.

Both fillers produce comparable long-term girth augmentation and satisfaction when assessed at 18 months, and both are considered safe with low complication rates in the available penile-augmentation literature.[5][4]

See also​

HA Filler — Penile Girth Augmentation · Cosmetic Genital Surgery — Male · Small Penis Syndrome / PDD · Penile Traction Therapy · Vacuum Erection Device

References​

1. Yang DY, Ko K, Lee SH, et al. Efficacy and safety of a newly developed polylactic acid microsphere as an injectable bulking agent for penile augmentation: 18-months follow-up. Int J Impot Res. 2017;29(4):136-141. doi:10.1038/ijir.2017.10

2. Vleggaar D, Fitzgerald R, Lorenc ZP. Composition and mechanism of action of poly-L-lactic acid in soft tissue augmentation. J Drugs Dermatol. 2014;13(4 Suppl):s29-31.

3. Yang DY, Ko K, Lee SH, Lee WK. A comparison of the efficacy and safety between hyaluronic acid and polylactic acid filler injection in penile augmentation: a multicenter, patient/evaluator-blinded, randomized trial. J Sex Med. 2019;16(4):577-585. doi:10.1016/j.jsxm.2019.01.310

4. Yang DY, Jeong HC, Ahn ST, et al. A comparison between hyaluronic acid and polylactic acid filler injections for temporary penile augmentation in patients with small penis syndrome: a multicenter, patient/evaluator-blind, comparative, randomized trial. J Sex Med. 2020;17(1):133-141. doi:10.1016/j.jsxm.2019.10.006

5. Yang DY, Jeong HC, Ko K, et al. Comparison of clinical outcomes between hyaluronic and polylactic acid filler injections for penile augmentation in men reporting a small penis: a multicenter, patient-blinded/evaluator-blinded, non-inferiority, randomized comparative trial with 18 months of follow-up. J Clin Med. 2020;9(4):E1024. doi:10.3390/jcm9041024

6. Haykal D, Haddad A, Cartier H, Avelar L. Poly-L-lactic acid in aesthetic dermatology: a decade beyond volume restoration toward regenerative biostimulation. Aesthet Surg J. 2025;sjaf121. doi:10.1093/asj/sjaf121

7. Oh S, Seo SB, Kim G, et al. Poly-D,L-lactic acid filler increases extracellular matrix by modulating macrophages and adipose-derived stem cells in aged animal skin. Antioxidants (Basel). 2023;12(6):1204. doi:10.3390/antiox12061204

8. Huth S, Huth L, Marquardt Y, et al. Molecular insights into the effects of PLLA-SCA on gene expression and collagen synthesis in human 3D skin models containing macrophages. J Drugs Dermatol. 2024;23(4):285-288. doi:10.36849/JDD.7791

9. Vleggaar D, Fitzgerald R, Lorenc ZP, et al. Consensus recommendations on the use of injectable poly-L-lactic acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s44-51.

10. Jabbar A, Arruda S, Sadick N. Off face usage of poly-L-lactic acid for body rejuvenation. J Drugs Dermatol. 2017;16(5):489-494.

11. Simamora P, Chern W. Poly-L-lactic acid: an overview. J Drugs Dermatol. 2006;5(5):436-440.

12. Butterwick K, Lowe NJ. Injectable poly-L-lactic acid for cosmetic enhancement: learning from the European experience. J Am Acad Dermatol. 2009;61(2):281-293. doi:10.1016/j.jaad.2008.11.881

13. Zhang CL, Quan Y, Li H, et al. Penile augmentation with injectable hyaluronic acid gel: an alternative choice for small penis syndrome. Asian J Androl. 2022;24(6):601-606. doi:10.4103/aja20223

14. Brandt FS, Cazzaniga A, Baumann L, et al. Investigator global evaluations of efficacy of injectable poly-L-lactic acid versus human collagen in the correction of nasolabial fold wrinkles. Aesthet Surg J. 2011;31(5):521-528. doi:10.1177/1090820X11411161

15. Vleggaar D, Fitzgerald R, Lorenc ZP. Understanding, avoiding, and treating potential adverse events following the use of injectable poly-L-lactic acid for facial and nonfacial volumization. J Drugs Dermatol. 2014;13(4 Suppl):s35-9.

16. Alijotas-Reig J, Garcia-Gimenez V, Vilardell-Tarres M. Late-onset immune-mediated adverse effects after poly-L-lactic acid injection in non-HIV patients: clinical findings and long-term follow-up. Dermatology. 2009;219(4):303-308. doi:10.1159/000243804

17. Wortsman X, Valderrama Y, Ortiz-Orellana G, et al. International multicentric study on ultrasound characteristics, layer location, and corporal distribution of granulomas after cosmetic fillers injections. J Ultrasound Med. 2025;44(8):1447-1455. doi:10.1002/jum.16700

18. O'Daniel G. Management of late-onset, recurrent facial nodular reaction after poly-L-lactic (PLLA) injections. J Drugs Dermatol. 2017;16(12):1297-1299.

19. Lam SM, Azizzadeh B, Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg. 2006;118(3 Suppl):55S-63S. doi:10.1097/01.prs.0000234612.20611.5a

20. Bartus C, William Hanke C, Daro-Kaftan E. A decade of experience with injectable poly-L-lactic acid: a focus on safety. Dermatol Surg. 2013;39(5):698-705. doi:10.1111/dsu.12128

21. Salloum A, Bazzi N, Haber R. Nonsurgical methods for penile augmentation: a systematic review. Dermatol Surg. 2021;47(3):e81-e85. doi:10.1097/DSS.0000000000002816

22. Manfredi C, Romero Otero J, Djinovic R. Penile girth enhancement procedures for aesthetic purposes. Int J Impot Res. 2022;34(4):337-342. doi:10.1038/s41443-021-00459-y